

THE MALTA COLLEGE OF PHARMACY PRACTICE
PROFESSIONAL DEVELOPMENT PROGRAMME - AUTUMN 2011

IS BEING SUPPORTED BY



Malta College
of Pharmacy Practice

www.mcppnet.org

MALTA COLLEGE OF PHARMACY PRACTICE

CONTINUING PROFESSIONAL DEVELOPMENT PROGRAMME AUTUMN 2011

Renewal of Membership

October 2011 - September 2012


- €22 Full Member (>30 credits)
- €25 Associate Member (< 30 credits)
- €25 New Member

In the interest of efficiency we would like to urge pharmacists to pay their membership in advance. Cheques should be made payable to: The Malta College of Pharmacy Practice. Cheques should be mailed to: Dr Maria Cordina, President, Malta College of Pharmacy Practice, c/o Department of Clinical Pharmacology & Therapeutics, University of Malta, Msida

For clarification of membership status and amount payable you may send an email to: registrar@mcppnet.org

in collaboration with
Department of Clinical Pharmacology & Therapeutics
University of Malta

Continuing Professional Development Cycle



Session	Date	Book by
1 Role of topical antibiotics	19 October	12 October
2 Medicines and DNA	26 October	19 October
3 Pharmacogenetics	2 November	26 October
4 Ethical and regulatory	9 November	2 November
5 Biomarkers	16 November	9 November

Exclusive attendance

All registered pharmacists are invited to become members of the Malta College of Pharmacy Practice and attend. Only registered pharmacists are eligible to become members of the College and thus participate in the events organised.

Students wishing to attend should send an email to: president@mcppnet.org


- Identify knowledge gaps through personal assessment
- Select appropriate learning activities
- Participate in activities
- Document activities as proof of participation
- Evaluate the success of your activity

BOOKING

may be placed preferably by email
info@mcppnet.org

Update your details online
www.mcppnet.org

**Why don't
medicines
always
work?**



Dear Colleague

We may have been faced with the situation of an appropriately used medicine not having the desired therapeutic effect. While a variety of factors may contribute to this, modern science is giving us a better insight into the manner that an individual's DNA affects response to drug therapy. Throughout this session we are therefore addressing an innovative topic, one which is influencing the practice of drug selection and interpretation of drug therapy outcomes. We would very much like to thank our speakers for their contribution. We would also like to thank our sponsors for their ongoing support of the College and its activities.

Maria Cordina

BPharm(Hons), PhD(QUB), Dip Health Outcomes Research
President, Malta College of Pharmacy Practice

SESSION 1 Emergency of community MRSA in Malta

What is the role of topical antibiotics and how can we address it?

Scope

Methicillin Resistant *Staphylococcus aureus* (MRSA) has long been an important pathogen in hospitals. However recent studies suggest that, throughout Europe, MRSA is also emerging in the community, with significant morbidity repercussions. One of the most important drivers for MRSA in the community is antibiotic use. Topical antibiotics have been shown to be especially important because of pharmacokinetic issues. This appears to be particularly relevant locally; community MRSA is increasing at a rapid rate and the proportion of colonised patients is one of the highest in the world; a link to the use of topical antibiotics, especially fusidic acid, has been suggested.

Objectives

- To provide an overview of community MRSA
- To highlight the role of antibiotics in the emergence of these organisms
- To discuss the risks posed by indiscriminate use of topical and systemic antibiotics
- To make recommendations for better practice

Learning objectives

By the end of the session the pharmacist will better understand:

- Community MRSA epidemiology in Malta
- The role of antibiotics as drivers of antimicrobial resistance
- The risk of topical antibiotics in MRSA emergence.
- Fundamental principals related to the correct use of topical antibiotics

Delivered by Michael A Borg

MD, MSc, DLSHTM, DipHIC, FMCPath, FRCPath, PhD
Chair: Infection Control Committee, Mater Dei Hospital

The presentation will be followed by a panel discussion with representatives from the Medicines Authority and the Pharmacy Council.

Date Wednesday, 19 October 2011
Time 19:30 for 20:00
Venue Lecture Centre, Car park 2
University of Malta
Book by Wednesday, 12 October 2011

This workshop provides 4 credits towards the MCPP continuing education requirement.

SESSION 2 Medicines and DNA

Scope

Some patients do not respond adequately to certain medicines, even though the dose may have been adjusted for known parameters such as age or weight. One possible reason for this patient to patient variability, lies in the differences between the DNA of different individuals. During the last two decades, great strides have been made in identifying and understanding these DNA differences. These areas of study, known as pharmacogenetics and pharmacogenomics, have immense applications in the way medicines are used, since they provide a means of predicting a drug response in a particular patient, by carrying out DNA testing prior to actually prescribing the medicine. This approach greatly contributes to the concept of personalized medicine, and opens up opportunities to safer drug use, improved therapeutic outcomes and improved healthcare.

Objectives

- To discuss the influence of DNA variability, on the therapeutic and adverse effects produced by medicines
- To provide a general overview as to how this information is being applied to improve the outcomes of drug therapy
- To discuss some practical examples which the pharmacist may come into contact with

Learning objectives

By the end of the session pharmacists will be better able to:

- Appreciate the roles of DNA in drug actions
- Understand the concept of genotype-guided prescribing

Delivered by Anthony Fenech

BPharm (Hons), MPhil, PhD (Nottingham)
Senior Lecturer, Department of Clinical Pharmacology and Therapeutics, University of Malta
Former Member, Pharmacogenetics Working Party (PgWP), European Medicines Agency

Date Wednesday, 26 October 2011
Time 19:30 for 20:00
Venue Lecture Centre, Car park 2
University of Malta
Book by Wednesday, 19 October 2011

This workshop provides 4 credits towards the MCPP continuing education requirement.

SESSION 3 Pharmacogenetics in practice

Scope

Practical applications for pharmacogenetics, may be better appreciated by discussing the therapeutic management of clinical cases. As a discipline, pharmacogenetics does not aim to replace optimization of drug dosing through clinical assessment or therapeutic drug monitoring, but rather act as a tool to enable improved choice of the best drug, administered at the right dose for a specific patient. This session will enact a practical scenario of therapeutic decision making, in the light of these aspects.

Objectives

- To appreciate the practical applications of pharmacogenetic testing
- To understand how pharmacogenetic testing may be integrated into the therapeutic decision making process

Learning objectives

By the end of the session pharmacists will be better able to:

- Appreciate the predictive contribution of pharmacogenetic testing in therapeutic decision making

Delivered by Anthony Fenech

BPharm (Hons), MPhil, PhD (Nottingham)
Senior Lecturer, Department of Clinical Pharmacology and Therapeutics, University of Malta
Former Member, Pharmacogenetics Working Party (PgWP), European Medicines Agency

Ruth Theuma

BPharm (Hons), MSc Clinical Pharmacy (Aberdeen)
Senior Clinical Pharmacist, Mater Dei Hospital

Lorna Marie West

BPharm (Hons), MSc Clinical Pharmacy (Aberdeen)
Senior Clinical Pharmacist, Mater Dei Hospital

Valeria Vella

BPharm (Hons), MSc Clinical Pharmacy (Aberdeen)
Senior Clinical Pharmacist, Mater Dei Hospital

Date Wednesday, 2 November 2011
Time 19:30 for 20:00
Venue Lecture Centre, Car park 2
University of Malta
Book by Wednesday, 26 October 2011

This workshop provides 4 credits towards the MCPP continuing education requirement.

SESSION 4 Ethical and regulatory issues in pharmacogenetics

Scope

This lecture will provide an overview of the regulatory mechanisms, and the underlying ethics context, in which pharmacogenetics will operate within the clinical and community setting.

Objectives

The lecture will provide information about:

- Developments on the regulatory process of pharmacogenetics as being discussed by EMA, FDA and ICH
- Case studies of drugs whose labelling requirements have changed following pharmacogenetic studies
- Ethical issues which ethical committees and the health care professionals are facing in the implementation of novel pharmacogenetic knowledge

Learning objectives

By the end of the session pharmacists will:

- Understand the various international regulatory processes involved in pharmacogenetic pharmaceutical care
- Be able to identify and understand the relevance of ethical issues in pharmacogenetics
- Be able to contextualise the various regulatory and ethical issues involved, using case studies
- Be able to address novel pharmacogenetic requirements in the community setting, in an ethical framework

Delivered by Bridget Ellul

MB ChB, MRCPPath, FRCPath
Head, Department of Pathology, University of Malta

Janet Mifsud

BPharm(Hons), PhD(QUB)
Senior Lecturer, Department of Clinical Pharmacology and Therapeutics, University of Malta
Former Member, Pharmacogenetics Working Party (PgWP), European Medicines Agency

Date Wednesday, 9 November 2011
Time 19:30 for 20:00
Venue Lecture Centre, Car park 2
University of Malta
Book by Wednesday, 2 November 2011

This workshop provides 4 credits towards the MCPP continuing education requirement.

SESSION 5 Biomarkers in drug therapy

Scope

Biomarkers are molecules that can be measured and used as patient classifiers and predictors of therapy outcome within specific patient groups. Individualised medicine is gaining importance especially in the treatment of oncology patients. To enhance improvement in survival rates of cancer patients, and the fact that new medicines are being introduced at a remarkable pace, individualized medicine will allow identification of specific therapeutic groups and will support the efforts for a continuous improvement in patient benefit. Predictive molecular markers are being continuously identified and include protein markers that define the cell state in specific groups of patients and also DNA markers that give information on the potential response / resistance to targeted drugs.

Objectives

- To address the use of molecular markers to classify patients into therapeutic groups
- To understand the use of genetic markers to predict therapy outcome
- To address the importance of molecular pathology in the clinic

Learning objectives

By the end of the session pharmacists will be better able to:

- Appreciate the role of biomarkers in the classification of patients
- Appreciate the role of biomarkers to predict therapy outcome
- Understand molecular responses and their use in patient management
- Understand the concept of risk-adaptive therapy

Delivered by Godfrey Grech

BSc, MPhil, PhD (Erasmus Medical Centre, Rotterdam, the Netherlands)
Senior Lecturer, Department of Pathology
University of Malta

Date Wednesday, 16 November 2011
Time 19:30 for 20:00
Venue Lecture Centre, Car park 2
University of Malta
Book by Wednesday, 9 November 2011

This workshop provides 4 credits towards the MCPP continuing education requirement.

PHARMACEUTICAL CARE

*...is the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life...
...is provided for the direct benefit of the patient and the pharmacist is responsible directly to the patient for the quality of that care."*

C.D. Hepler

MCPP General Meeting

The General meeting of the Malta College of Pharmacy Practice will be held on Wednesday 19th October 2011 at 7:30pm at the Lecture centre University of Malta.

Nominations for the post of President and Members of the Council by full members will be received for the forthcoming elections by Wednesday, 19th October. Elections will only be held if the number of nominations exceeds the number of Council posts.

Nomination forms may be downloaded from www.mcppnet.org